These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35609779)

  • 21. Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial.
    Onichimowski D; Będźkowska A; Ziółkowski H; Jaroszewski J; Borys M; Czuczwar M; Wiczling P
    Pharmacol Rep; 2020 Jun; 72(3):719-729. PubMed ID: 32301057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy.
    Thy M; Urien S; Foissac F; Bouazza N; Gana I; Bille E; Béranger A; Toubiana J; Berthaud R; Lesage F; Renolleau S; Tréluyer JM; Benaboud S; Oualha M
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0113522. PubMed ID: 36342152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimization of polymyxin B regimens for the treatment of carbapenem-resistant organism nosocomial pneumonia: a real-world prospective study.
    Tang T; Li Y; Xu P; Zhong Y; Yang M; Ma W; Xiang D; Zhang B; Zhou Y
    Crit Care; 2023 Apr; 27(1):164. PubMed ID: 37106370
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population Pharmacokinetic Modeling Using Polymyxin B Free Plasma Concentrations From Published Reports and Evaluation of Dosage Regimens Based on Monte Carlo Simulation in Critically Ill Patients.
    Zheng Y; Xu B; Chen S; Liu M; Huang H; Wang J; Wu X
    J Clin Pharmacol; 2023 Sep; 63(9):1036-1044. PubMed ID: 37125471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic and Pharmacodynamic Analysis of Critically Ill Patients Undergoing Continuous Renal Replacement Therapy With Imipenem.
    Li Z; Bai J; Wen A; Shen S; Duan M; Li X
    Clin Ther; 2020 Aug; 42(8):1564-1577.e8. PubMed ID: 32741646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Daily fluid intake as a novel covariate affecting the population pharmacokinetics of polymyxin B in patients with sepsis.
    Wang P; Liu S; Sun T; Yang J
    Int J Antimicrob Agents; 2024 Mar; 63(3):107099. PubMed ID: 38280575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy.
    Al-Shaer MH; Philpott CD; Droege CA; Courter JD; Healy DP; Droege ME; Ernst NE; Mueller EW; Peloquin CA
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33722885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing ceftaroline dosing in critically ill patients undergoing continuous renal replacement therapy.
    Kalaria S; Williford S; Guo D; Shu Y; Medlin C; Li M; Yeung SYA; Ali F; Jean W; Gopalakrishnan M; Heavner M
    Pharmacotherapy; 2021 Feb; 41(2):205-211. PubMed ID: 33438291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics and simulations of imipenem in critically ill patients undergoing continuous renal replacement therapy.
    Li S; Xie F
    Int J Antimicrob Agents; 2019 Jan; 53(1):98-105. PubMed ID: 30626495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population Pharmacokinetics of Polymyxin B and Dosage Optimization in Renal Transplant Patients.
    Li Y; Deng Y; Zhu ZY; Liu YP; Xu P; Li X; Xie YL; Yao HC; Yang L; Zhang BK; Zhou YG
    Front Pharmacol; 2021; 12():727170. PubMed ID: 34512352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study.
    Broeker A; Wicha SG; Dorn C; Kratzer A; Schleibinger M; Kees F; Heininger A; Kees MG; Häberle H
    Crit Care; 2018 Dec; 22(1):341. PubMed ID: 30558639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.
    Isla A; Rodríguez-Gascón A; Trocóniz IF; Bueno L; Solinís MA; Maynar J; Sánchez-Izquierdo JA; Pedraz JL
    Clin Pharmacokinet; 2008; 47(3):173-80. PubMed ID: 18307371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative polymyxin B pharmacokinetics in critically ill patients with renal insufficiency and in continuous veno-venous hemodialysis.
    Surovoy YA; Burkin MA; Galvidis IA; Sobolev MA; Rende OC; Tsarenko SV
    Eur J Clin Pharmacol; 2023 Jan; 79(1):79-87. PubMed ID: 36378296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.
    Dubinsky S; Watt K; Saleeb S; Ahmed B; Carter C; Yeung CHT; Edginton A
    Clin Pharmacokinet; 2022 Feb; 61(2):189-229. PubMed ID: 34846703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cefiderocol Dosing for Patients Receiving Continuous Renal Replacement Therapy.
    Wei X; Naseer S; Weinstein EA; Iarikov D; Nambiar S; Reynolds KS; Jang SH
    Clin Pharmacol Ther; 2022 Nov; 112(5):1004-1007. PubMed ID: 35792715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meropenem Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy.
    Thy M; Urien S; Bouazza N; Foissac F; Gana I; Bille E; Béranger A; Toubiana J; Berthaud R; Lesage F; Renolleau S; Tréluyer JM; Benaboud S; Oualha M
    Clin Pharmacokinet; 2022 Nov; 61(11):1609-1621. PubMed ID: 36251162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of trimethoprim/sulfametrole in critically ill patients on continuous renal replacement therapy.
    Welte R; Beyer R; Hotter J; Broeker A; Wicha SG; Gasperetti T; Ranke P; Zaruba MM; Lorenz I; Eschertzhuber S; Ströhle M; Bellmann-Weiler R; Joannidis M; Bellmann R
    J Antimicrob Chemother; 2020 May; 75(5):1237-1241. PubMed ID: 31990343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and pharmacodynamics of polymyxin B and proposed dosing regimens in elderly patients with multi-drug-resistant Gram-negative bacterial infections.
    Wang P; Liu D; Sun T; Zhang X; Yang J
    Int J Antimicrob Agents; 2022; 60(5-6):106693. PubMed ID: 36375775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aminoglycoside Pharmacokinetics in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.
    Krueger CK; Bruno JJ; Tverdek FP; Hernandez M; Abudayyeh A
    Ann Pharmacother; 2023 Jun; 57(6):629-636. PubMed ID: 36062536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Applying Cefepime Population Pharmacokinetics to Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
    Al-Shaer MH; Maguigan K; Ashton J; Venugopalan V; Droege ME; Philpott CD; Droege CA; Healy DP; Mueller EW; Peloquin CA
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0161121. PubMed ID: 34662194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.